Vicente Anido, Aerie CEO (University of West Virginia via YouTube)

Who needs pri­ma­ry end­points any­way? Aerie touts sil­ver lin­ings from failed PhI­Ib, plots PhI­II in dry eye dis­ease

Aerie’s dry eye dis­ease drug may not have met the pri­ma­ry end­points it’s cho­sen for a Phase IIb study, but that’s not stop­ping the biotech from pow­er­ing through Phase III — and steer­ing to­ward a field with plen­ty of ri­vals.

“While we did not achieve sta­tis­ti­cal sig­nif­i­cance at our pre-de­ter­mined pri­ma­ry end­points at Day 28, as a re­minder, this is a Phase 2b study where se­lect­ing pri­ma­ry end­points are not re­quired,” CEO Vi­cente Anido said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.